MX2010007699A - Tratamiento de enfermedades del colon o prevencion de carcinoma colorrectal con derivados de imidazoquinolina. - Google Patents

Tratamiento de enfermedades del colon o prevencion de carcinoma colorrectal con derivados de imidazoquinolina.

Info

Publication number
MX2010007699A
MX2010007699A MX2010007699A MX2010007699A MX2010007699A MX 2010007699 A MX2010007699 A MX 2010007699A MX 2010007699 A MX2010007699 A MX 2010007699A MX 2010007699 A MX2010007699 A MX 2010007699A MX 2010007699 A MX2010007699 A MX 2010007699A
Authority
MX
Mexico
Prior art keywords
prevention
treatment
colorectal carcinoma
imidazo
colon diseases
Prior art date
Application number
MX2010007699A
Other languages
English (en)
Inventor
Istvan Szelenyi
Joachim Maus
Ursula Petzold
Original Assignee
Meda Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40419193&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2010007699(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Meda Ab filed Critical Meda Ab
Publication of MX2010007699A publication Critical patent/MX2010007699A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Abstract

La invención se refiere al tratamiento de enfermedades colorrectales tales como pólipos, etapas precancerosas y prevención y tratamiento adyuvante del cáncer colorrectal por medio de la administración tópica de fármacos inmunomoduladores de la familia de imidazoquinolina tal como imiquimod (1-(2-metilpropil)-1H-imidazo[4,5-c]quinolin-4-amina), resiquimod (4-amino-a,a-dimetil-2-etoximetil-1H-imidazo[4,5-c]quinolin-1-eta nol), sotirímod (2-metil-1-(2-metil-propil)-1H-imidazo[4,5-c][1,5] naftiridin-4-amina).
MX2010007699A 2008-01-15 2008-12-23 Tratamiento de enfermedades del colon o prevencion de carcinoma colorrectal con derivados de imidazoquinolina. MX2010007699A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US645908P 2008-01-15 2008-01-15
PCT/EP2008/011088 WO2009089900A1 (en) 2008-01-15 2008-12-23 Treatment of colon diseases or prevention of colorectal carcinoma with imidazoquinoline derivatives

Publications (1)

Publication Number Publication Date
MX2010007699A true MX2010007699A (es) 2010-08-04

Family

ID=40419193

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010007699A MX2010007699A (es) 2008-01-15 2008-12-23 Tratamiento de enfermedades del colon o prevencion de carcinoma colorrectal con derivados de imidazoquinolina.

Country Status (15)

Country Link
US (1) US8008319B2 (es)
EP (1) EP2237780A1 (es)
JP (1) JP2011509956A (es)
CN (1) CN101909624A (es)
AU (1) AU2008347400B2 (es)
BR (1) BRPI0822002A2 (es)
CA (1) CA2708559C (es)
EA (1) EA018579B1 (es)
GE (1) GEP20125605B (es)
IL (1) IL205819A (es)
MX (1) MX2010007699A (es)
NZ (1) NZ586161A (es)
UA (1) UA101339C2 (es)
WO (1) WO2009089900A1 (es)
ZA (1) ZA201003906B (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5694345B2 (ja) 2009-10-22 2015-04-01 ギリアード サイエンシーズ， インコーポレイテッド Ｔｏｌｌ様受容体の調節因子
CN112587658A (zh) 2012-07-18 2021-04-02 博笛生物科技有限公司 癌症的靶向免疫治疗
CA2936377A1 (en) 2014-01-10 2015-07-16 Shanghai Birdie Biotech, Inc. Compounds and compositions for treating egfr expressing tumors
KR102462743B1 (ko) 2014-07-09 2022-11-02 버디 바이오파마슈티칼즈, 인크. 종양 치료용 항-pd-l1 조합
CN112587672A (zh) 2014-09-01 2021-04-02 博笛生物科技有限公司 用于***的抗-pd-l1结合物
CN106943597A (zh) 2016-01-07 2017-07-14 博笛生物科技（北京）有限公司 用于***的抗-egfr组合
CN115554406A (zh) 2016-01-07 2023-01-03 博笛生物科技有限公司 用于***的抗-cd20组合
CN106943598A (zh) 2016-01-07 2017-07-14 博笛生物科技（北京）有限公司 用于***的抗-her2组合
CN108794467A (zh) 2017-04-27 2018-11-13 博笛生物科技有限公司 2-氨基-喹啉衍生物
WO2018232725A1 (en) 2017-06-23 2018-12-27 Birdie Biopharmaceuticals, Inc. PHARMACEUTICAL COMPOSITIONS

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2078547C1 (ru) * 1995-11-28 1997-05-10 Центральный научно-исследовательский рентгено-радиологический институт МЗМП РФ Способ лечения полипоза желудка и двенадцатиперстной кишки
UA74852C2 (en) * 2000-12-08 2006-02-15 3M Innovative Properties Co Urea-substituted imidazoquinoline ethers
EP1351678A2 (en) * 2001-01-02 2003-10-15 Elizabeth Shanahan-Prendergast Treatment for inhibiting neoplastic lesions using incensole and/or furanogermacrens
US20060193789A1 (en) * 2002-10-25 2006-08-31 Foamix Ltd. Film forming foamable composition
AU2004295061B2 (en) * 2003-11-21 2008-11-20 Novartis Ag 1H-imidazoquinoline derivatives as protein kinase inhibitors

Also Published As

Publication number Publication date
IL205819A (en) 2013-02-28
US8008319B2 (en) 2011-08-30
WO2009089900A1 (en) 2009-07-23
AU2008347400B2 (en) 2014-12-11
US20090182005A1 (en) 2009-07-16
UA101339C2 (ru) 2013-03-25
CA2708559C (en) 2015-10-06
AU2008347400A1 (en) 2009-07-23
GEP20125605B (en) 2012-08-10
EA201001164A1 (ru) 2010-12-30
EA018579B1 (ru) 2013-09-30
ZA201003906B (en) 2011-03-30
CA2708559A1 (en) 2009-07-23
JP2011509956A (ja) 2011-03-31
IL205819A0 (en) 2010-11-30
CN101909624A (zh) 2010-12-08
BRPI0822002A2 (pt) 2015-10-13
NZ586161A (en) 2012-05-25
EP2237780A1 (en) 2010-10-13

Similar Documents

Publication Publication Date Title
MX2010007699A (es) Tratamiento de enfermedades del colon o prevencion de carcinoma colorrectal con derivados de imidazoquinolina.
CY1119844T1 (el) 1η-πυραζολο[3,4-β]πυριδινες και θεραπευτικες χρησεις αυτων
MX2019010601A (es) Terapia de combinacion para tratar cancer.
WO2012143416A3 (en) 7 - (3,5 - dimethyl - 4 - isoxazolyl) - 8 - (methyloxy) - 1h - imidazo [4,5 -c] quinoline derivatives
MX350597B (es) 4- (8 - metoxi - 1 - ( (1 - metoxipropan - 2 - il) - 2 - (tetrahidro - 2h - piran - 4 - il) - 1 h - imidazo [4,5-c] quinolin -7 - il ) -3,5 - dimetilisoxazol y su uso como inhibidor de bromodominio.
TN2013000237A1 (en) Imidazo [4, 5 -c] quinolin- 2 -one compound and its use as pi3 kinase / mtor dual inhibitor
PH12015500940A1 (en) Bruton`s tyrosine kinase inhibitors
MX2016006119A (es) Derivados de 1-(5-terc-butil-2-aril-pirazol-3-il)-3-[2-fluoro-4-[( 3-oxo-4h-pirido[2,3 b]piracin-8-il)oxi]fenil]urea como inhibidores de raf para el tratamiento del cancer.
MX2016007351A (es) Terapia de combinacion para tratar cancer.
NZ607060A (en) Substituted imidazoquinoline derivatives as kinase inhibitors
HK1139930A1 (en) Cyclopamine lactam analogs and methods of use thereof
MY185666A (en) Anticancer pyridopyrazines via the inhibition of fgfr kinases
UA118645C2 (uk) Спосіб комбінованої терапії раку наночастинками, що містять рапаміцин і альбумін
MX362939B (es) Derivados de (aza-)isoquinolinona.
EA201100971A1 (ru) Производные пиримидининдола для лечения злокачественного новообразования
MX366899B (es) Nuevos compuestos.
ZA201200705B (en) Imidazo [4,5-c]quinoline derivatives and their use in the treatment of tumors and/or inflammation
PH12014501829A1 (en) Bicyclic pyrazinone derivatives
UA110213C2 (en) Use of sigma-ligand induced opioid hyperalgesia
TNSN07193A1 (en) Pharmaceutical compositions comprising a camptothecin derivate
AU2013218357A8 (en) Tetrahydro-quinazolinone derivatives as TANK and PARP inhibitors
MX359656B (es) Derivados de oxoquinazolinil-butanamida.
WO2009087091A8 (en) Formulations for the treatment of mucositis induced by antitumor or immunosuppressive therapy
EP3345597A3 (en) Pkc delta inhibitors for use as therapeutics
JP2006504721A5 (es)

Legal Events

Date Code Title Description
FG Grant or registration